[Pharmacokinetics of aztreonam on hemodialysis].
We studied the pharmacokinetics of aztreonam (AZT) in 6 patients with renal insufficiencies during nonhemodialysis and hemodialysis. After intravenous injection of 1 g AZT, it was found that serum AZT concentrations during hemodialysis were different from those during nonhemodialysis and serum half-lives (T 1/2 beta) were 3.44 hours and 16.97 hours, respectively. AZT clearance changed from 0.762 L/hr during hemodialysis to 3.360 L/hr during nonhemodialysis. These findings suggest that hemodialysis patients should receive the standard dose of AZT as a loading dose, followed by one-half the loading dose per day and receive a supplemental dose equal to half their usual maintenance dose after each dialysis session.
Nagasaka
H
H
Dialysis Unit, Hyogo College of Medicine.
Inagaki
O
O
Nasu
M
M
Nakagawa
K
K
Nishian
Y
Y
Hiraoka
K
K
Syono
T
T
Azuma
M
M
Hirabayashi
T
T
Mori
H
H
D000368:Aged; D001398:Aztreonam / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007674:Kidney Diseases / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D011485:Protein Binding; D006435:Renal Dialysis
D001398:Aztreonam